JP6829928B2 - 二相性単鎖インスリン類似体 - Google Patents

二相性単鎖インスリン類似体 Download PDF

Info

Publication number
JP6829928B2
JP6829928B2 JP2017518189A JP2017518189A JP6829928B2 JP 6829928 B2 JP6829928 B2 JP 6829928B2 JP 2017518189 A JP2017518189 A JP 2017518189A JP 2017518189 A JP2017518189 A JP 2017518189A JP 6829928 B2 JP6829928 B2 JP 6829928B2
Authority
JP
Japan
Prior art keywords
insulin
chain insulin
chain
amino acid
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017518189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536337A (ja
JP2017536337A5 (enExample
Inventor
ワイス、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of JP2017536337A publication Critical patent/JP2017536337A/ja
Publication of JP2017536337A5 publication Critical patent/JP2017536337A5/ja
Application granted granted Critical
Publication of JP6829928B2 publication Critical patent/JP6829928B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017518189A 2014-10-06 2015-10-06 二相性単鎖インスリン類似体 Active JP6829928B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060167P 2014-10-06 2014-10-06
US62/060,167 2014-10-06
PCT/US2015/054263 WO2016057529A2 (en) 2014-10-06 2015-10-06 Biphasic single-chain insulin analogues

Publications (3)

Publication Number Publication Date
JP2017536337A JP2017536337A (ja) 2017-12-07
JP2017536337A5 JP2017536337A5 (enExample) 2018-11-08
JP6829928B2 true JP6829928B2 (ja) 2021-02-17

Family

ID=55653938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518189A Active JP6829928B2 (ja) 2014-10-06 2015-10-06 二相性単鎖インスリン類似体

Country Status (10)

Country Link
US (2) US10392429B2 (enExample)
EP (1) EP3204410B1 (enExample)
JP (1) JP6829928B2 (enExample)
KR (1) KR102569743B1 (enExample)
CN (1) CN107108716B (enExample)
AU (1) AU2015328222B9 (enExample)
BR (1) BR112017004544A2 (enExample)
CA (1) CA2961037A1 (enExample)
IL (1) IL251503A0 (enExample)
WO (1) WO2016057529A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936563A1 (en) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
HK1255634A1 (zh) * 2015-12-23 2019-08-23 Case Western Reserve University 超稳胰岛素类似物在聚合物熔体中的包囊
AU2017361524B2 (en) * 2016-11-21 2022-06-02 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
HUE062719T2 (hu) * 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
BR112021005366A2 (pt) * 2018-09-21 2021-06-29 Case Western Reserve University análogo de insulina de cadeia simples, uso deste e método para reduzir o açúcar no sangue de um paciente
US12077568B2 (en) 2018-10-01 2024-09-03 University Of Houston System Engineered active single-polypeptide chain insulin analogs
US20220002373A1 (en) * 2018-11-19 2022-01-06 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
CA3139946A1 (en) * 2019-05-17 2020-11-26 Case Western Reserve University Variant single-chain insulin analogues
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20220280614A1 (en) * 2019-08-02 2022-09-08 Case Western Reserve University Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations
IL296090A (en) * 2020-03-02 2022-11-01 Thermalin Inc Compositions containing rapid-acting insulin analogues
EP4255469A4 (en) * 2020-12-07 2025-01-22 Case Western Reserve University ACYLATED SINGLE-CHAIN INSULIN ANALOGUES
CZ310198B6 (cs) * 2021-07-07 2024-11-13 Ústav organické chemie a biochemie AV ČR, v. v. i. Deriváty inzulínu se zvýšenou tepelnou stabilitou
WO2023041758A1 (en) 2021-09-20 2023-03-23 Kyon Biotech Ag Arginase-insulin fusion protein
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
WO1990001038A1 (en) 1988-07-20 1990-02-08 Nordisk Gentofte A/S Human insulin analogs and preparations containing them
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DE3936876A1 (de) 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK158390D0 (da) 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
TW224471B (enExample) 1991-11-26 1994-06-01 Lilly Co Eli
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
DE19652713C2 (de) 1996-12-18 2001-11-22 Aventis Pharma Gmbh Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
AU2002346490A1 (en) 2001-12-20 2003-07-09 Eli Lilly And Company Insulin molecule having protracted time action
WO2003080666A2 (en) 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research An adipocyte insulin and a method of treating diabetes
JP4602075B2 (ja) 2002-05-06 2010-12-22 トーマス・ジェファーソン・ユニバーシティ 脳の健康に効果のあるインスリン関連ペプチド
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
TWI345587B (en) 2003-06-17 2011-07-21 Sembiosys Genetics Inc Methods for the production of insulin in plants
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
ATE513921T1 (de) * 2005-08-16 2011-07-15 Novo Nordisk As Verfahren zur herstellung reifer insulinpolypeptide
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US8192857B2 (en) 2006-03-04 2012-06-05 Enerdel, Inc. Battery assembly and method of forming the same
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
AU2009240636A1 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
WO2009133099A2 (en) * 2008-04-28 2009-11-05 Novo Nordisk A/S Insulin precursors for diabetes treatment
EP2318432B1 (en) 2008-07-31 2015-09-02 Case Western Reserve University Halogen-stabilized insulin
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
RU2012123642A (ru) 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
BR112012020481A2 (pt) 2010-02-22 2017-01-10 Univ Case Western Reserve método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.
JP5969469B2 (ja) * 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
MX2015005662A (es) * 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.

Also Published As

Publication number Publication date
EP3204410A4 (en) 2018-03-07
KR20170064533A (ko) 2017-06-09
WO2016057529A2 (en) 2016-04-14
BR112017004544A2 (en) 2018-01-23
WO2016057529A3 (en) 2016-11-03
EP3204410A2 (en) 2017-08-16
US10392429B2 (en) 2019-08-27
CN107108716B (zh) 2026-06-19
KR102569743B1 (ko) 2023-08-23
AU2015328222B9 (en) 2020-12-24
US20190375814A1 (en) 2019-12-12
CA2961037A1 (en) 2016-04-14
JP2017536337A (ja) 2017-12-07
CN107108716A (zh) 2017-08-29
US11142560B2 (en) 2021-10-12
AU2015328222A1 (en) 2017-03-16
US20180265560A1 (en) 2018-09-20
IL251503A0 (en) 2017-05-29
EP3204410B1 (en) 2021-01-20
AU2015328222B2 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US11142560B2 (en) Biphasic single-chain insulin analogues
US11174303B2 (en) Single-chain insulin analogues stabilized by a fourth disulfide bridge
JP6584953B2 (ja) 長時間作用型単鎖インスリン類似体
US20150299286A1 (en) Glutamic acid-stabilized insulin analogues
US10138284B2 (en) Non-standard insulin analogues
AU2013337250A1 (en) Long-acting single-chain insulin analogues
KR20120129875A (ko) 염소화 아미노산을 갖는 인슐린 유사체
JP2016516728A (ja) 第２部位インスリン類似体
KR20150110677A (ko) N 말단 절단된 인슐린 유사체
US20240043493A1 (en) Acylated single-chain insulin analogues
AU2013237740B2 (en) Insulin analogues containing penta-fluora-phenyalanine at position B24
HK1238651A1 (en) Biphasic single-chain insulin analogues
US20220280614A1 (en) Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations
HK40045373A (en) Long-acting single-chain insulin analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210123

R150 Certificate of patent or registration of utility model

Ref document number: 6829928

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250